Shangyi Zhilian and Xunzhen Da Announce Strategic Partnership to Democratize Gene Sequencing for Grassroots Healthcare

On February 15, 2022, Shangyi Zhilian (Guangzhou) Health Technology Co., Ltd. (hereinafter referred to as “Shangyi Zhilian”) joined hands with Shanghai Xuzhenda Biotechnology Co., Ltd. (hereinafter referred to as “Xuzhenda”) to hold a signing ceremony and execute a strategic cooperation agreement in Guangzhou. Ms. Zhai Chunjiu, General Manager of Shangyi Zhilian; Dr. Sun Lele, Founder and CEO of Xuzhenda; Mr. Fei Jiajun, Co-founder and CIO of Xuzhenda; and other attendees participated in the ceremony and completed the signing.

Signing Ceremony Between Xuzhenda, Dongchuang Health, 800 Fang, and Shangyi Zhilian

Mr. Zhang Zihao, General Manager of 800 Fang; Mr. Cai Xiaoyong, General Manager of Dongchuang Health; Mr. Zhang Xiaobing, Chairman of Dongchuang Health; Dr. Sun Lele, Founder and CEO of Xuzhenda; Ms. Zhai Chunjiu, General Manager of Shangyi Zhilian; and Mr. Fei Jiajun, Co-founder and CIO of Xuzhenda

At the ceremony, both parties reached a consensus to deeply integrate their respective advantageous resources, jointly promote the implementation of gene sequencing services at the grassroots level, expand the application fields and scope of gene sequencing, and advance the democratization of precision medicine. This initiative aims to transform sequencing technology—once unaffordable and difficult to utilize—into an accessible and effective public benefit service, thereby supporting the development of precision medicine at the grassroots level and benefiting a broader population.

Shangyi Zhilian & Xuzhenda

In this regard,Ms. Zhai Chunjiu, General Manager of Shangyi Zhilianstated, “As a data-driven service platform rooted in the primary healthcare market, Shangyi Zhilian adheres to the principle of ‘digging one kilometer deep within a one-centimeter scope.’ By leveraging appropriate technologies, specialized academic expertise, and laboratory applications, we fully utilize big data and artificial intelligence technologies. With the ‘doctor-patient interaction’ as the linking thread, we break down ‘data silos’ across systems and connect clinics, physicians, patients, and upstream health-related suppliers. This comprehensive approach supports primary care physicians in enhancing their diagnostic and treatment capabilities, making Shangyi Zhilian a trusted assistant for primary care doctors. The collaboration with Xuzhenda will leverage Shangyi’s digital management system and service reach, which covers millions of primary care physicians, to provide comprehensive grassroots implementation services for gene sequencing. This initiative aims to extend gene sequencing services to the primary care level, fill the gap in medical resource shortages in township areas, and help residents in primary care settings achieve early detection, early diagnosis, and early intervention for major diseases.”

Mr. Fei Jiajun, Co-founder and Chief Information Officer of Xuzhenda“Genomic sequencing is a crucial step in precision medicine and key to guiding treatment plans. It helps physicians develop rational therapeutic pathways, enabling patients to achieve cost-effective, rapid, and clinically effective outcomes. In China, the population of lower-tier cities reaches 930 million, with 66.6% residing in third-, fourth-, and fifth-tier cities. Due to economic, environmental, and educational constraints, awareness of early detection for major diseases remains severely inadequate, and testing infrastructure is significantly lacking. Consequently, advancing precision medicine at the grassroots level faces substantial challenges. To promote the development of grassroots precision medicine and shift from passive treatment to proactive prevention, training grassroots physicians and enhancing their service capabilities are critical to the successful implementation of related products. Grassroots physicians, who maintain close ties with county and township residents, have become the vanguard in popularizing precision medicine. Leveraging its years of experience and accumulation in grassroots markets, Shangyi Zhilian holds distinct advantages in bringing genomic sequencing to the grassroots level. Through a strategic partnership, Xuzhenda and Shangyi Zhilian join forces to empower grassroots physicians, enabling the application of affordable genomic sequencing technologies in more primary care settings and contributing to the democratization of precision medicine.”

Shanghai Xuzhenda Biotechnology Co., Ltd. is a leading multi-omics research and clinical service provider in China, dedicated to genomics, epigenomics, transcriptomics, proteomics, and other related services. Adhering to the principle of prioritizing research and centering on customers, the company supports pharmaceutical R&D enterprises in drug screening, biomarker discovery, and clinical trials. Xuzhenda Biotechnology offers a diverse range of genomic and proteomic assays validated under CLIA/CAP standards, including genotyping and gene expression qPCR assays, NGS assays, and protein biomarker assays. Its flagship assays include FoundationOne CDx, Illumina TSO500 for tissue and ctDNA, 10x Genomics single-cell solutions, Olink Target 96/48, Olink Explore 1536/384, as well as metagenomics, mRNA, small RNA (smRNA), whole-genome sequencing, and exome sequencing. Customized assays are also available based on project requirements.

Shangyi Zhilian (Guangzhou) Health Technology Co., Ltd. is a comprehensive health technology company dedicated to the mission of enabling primary care patients to access better medical services. Focusing on “specialty development at the primary care level,” the company is committed to empowering primary care specialties and providing all-around support to primary care outpatient physicians, thereby enhancing both the technical capabilities and operational efficiency of primary healthcare institutions. Centered on primary care outpatient services, it has built an integrated service platform combining “Internet + Primary Healthcare + Carefully Selected Products.” Supported by “data-driven” strategies, the company leverages appropriate technologies, specialized academic resources, and laboratory applications, while fully utilizing big data and artificial intelligence to improve medical service delivery. By fostering “doctor-patient interactions” as a connecting thread, it breaks down “data silos” across systems, linking clinics, physicians, patients, and upstream health-related suppliers to reconstruct industry services.